1. Treatment with lenalidomide and dexamethasone significantly delayed disease progression in patients with smoldering multiple myeloma who were at high risk for progression.
2. Treatment with lenalidomide and dexamethasone improved survival in such patients.
3. The treatment was associated with more adverse events than observation (current standard).
Evidence Rating Level: 1...